cardiovascular drugs News
-
Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programs for the prevention of cardiotoxicity and heart damage – an area of huge unmet need within the EU and globally
Genome Biologics UG, Frankfurt, Germany, today announced that they have been awarded up to 9.8 million euros of equity funding through the European Innovation Council (EIC) Accelerator program to accelerate their breakthrough innovations in cardiovascular drug discovery and development. Cardiovascular diseases account for the majority of mortality and disability globally, accounting for 32% of ...
-
EPA warns, “children act fast...so do poisons,” in observance of poison prevention week / national awareness campaign planned for March 20-26 to reduce poisonings in U.S.
In ongoing efforts to protect people’s health, the U.S. Environmental Protection Agency is collaborating with the Poison Prevention Week Council to encourage the public to keep poisonous substances out of the hands of children. In observance of National Poison Prevention Week (March 20-26), EPA recommends that locking household cleaners, disinfectants, solvents and other materials is the ...
-
ELIXIR MEDICAL EXPANDS BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
MILPITAS, Calif. – April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel ...
-
Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia - PharmiWeb.com
MALVERN, Pa.--(BUSINESS WIRE)--#Cardiovascular--Shifa Biomedical Corporation (Shifa), a drug discovery company developing an oral small molecule PCSK9/low density lipoprotein-cholesterol receptor (LDLR) antagonist, P-21, to treat dyslipidemia, today announced their launch with a seed investment from Xontogeny, LLC to advance their lead program through IND-enabling research. “We are excited ...
-
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation from a living donor. ...
-
Shifa Biomedical Corporation Presents Preclinical Data on P-21, a Novel Orally Active PSCK9 Antagonist, at the American Heart Association (AHA) Meeting, Scientific Sessions 2018
CHICAGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Shifa Biomedical Corporation (Shifa), a drug discovery biopharmaceutical company focused on developing novel agents to treat cardiovascular disease and hypercholesteremia, today announced exciting preclinical data involving the company’s pre-clinical candidate, P-21, which interferes with the interaction between PCSK9 and the LDL receptor (LDLR). ...
-
BIO Investor Forum Company Snapshot: InvivoSciences
BIO Investor Forum Company Snapshot: InvivoSciences What is your company’s lead product or technology? InvivoSciences, Inc. (IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. IVS’s Functional 3D ...
-
ELIXIR MEDICAL COMPLETES ENROLLMENT IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
MILPITAS, Calif. – February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for ...
-
ELIXIR MEDICAL ANNOUNCES FIRST PATIENT TREATED IN BIOADAPTOR RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents International Trial to Compare Bioadaptor, a MILPITAS, Calif. – January 13, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated ...
-
ELIXIR MEDICAL ANNOUNCES COMMENCEMENT OF INFINITY-SWEDEHEART RANDOMIZED CONTROLLED TRIAL OF DYNAMX CORONARY BIOADAPTOR SYSTEM
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif. – March 16, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized ...
-
Drug developed by Galveston scientist to be tested for COVID-19 use
A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems related to COVID-19, thanks to a $1.5 million grant from the federal government to be released June 1. Chrysalin, or TP508, a regenerative thrombin peptide developed by scientist Darrell Carney, has been tested in human clinical trials for skin and bone tissue repair ...
-
ELIXIR MEDICAL ANNOUNCES OUTSTANDING 24-MONTH DATA FOR DYNAMX CORONARY BIOADAPTOR SYSTEM, DEMONSTRATING STRONG SAFETY WITH NO TARGET LESION REVASCULARIZATION, MYOCARDIAL INFARCTION OR THROMBOSIS THROUGH 24 MONTHS
MILPITAS, Calif. – January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The results were presented at the 30th Annual Live Interventions in Vascular Endotherapy ...
-
Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design. Under the agreement, Iktos generative ...
By Iktos
-
Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza Phase IV and Duaklir Phase III Studies
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of positive clinical data from the Tudorza® Pressair® phase IV ASCENT study and Duaklir® Pressair® phase III AMPLIFY study at the American Thoracic Society (ATS) 2018 International ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you